- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04106856
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (SHAPER)
SHAPER: A Phase 1 Study of Losartan and Hypofractionated Radiation Therapy After Induction Chemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. To assess the safety of losartan potassium (losartan) in combination with hypofractionated radiation treatment for patients with stable or locally progressive pancreatic ductal adenocarcinoma (PDAC) after induction chemotherapy.
SECONDARY OBJECTIVES:
I. To assess the safety of losartan in combination with HRT for patients with stable or locally progressive PDAC after induction chemotherapy.
II. To assess the efficacy of losartan in combination with HRT for patients with stable or locally progressive PDAC after induction chemotherapy.
III. To assess the rate of hypotensive adverse events grade >= 3.
EXPLORATORY OBJECTIVE:
I. To assess patient reported quality of life.
OUTLINE:
Beginning day 1, patients receive losartan potassium orally (PO) once daily (QD). Beginning day 14, patients also undergo hypofractionated radiation therapy over 15 fractions 5 days a week for up to 3 weeks. Patients continue to receive losartan potassium PO QD during radiation therapy and for 28 days after completion of radiation therapy.
After completion of study treatment, patients are followed up at 28 and 84 days, every 3 months for 12 months, and then every 6 months for up to 36 months.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Mitchell Shea
- Phone Number: 801-587-4756
- Email: mitch.shea@hci.utah.edu
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed pancreatic ductal adenocarcinoma
- Borderline resectable or locally advanced unresectable pancreas cancer as defined by the National Comprehensive Cancer Network (NCCN) and determined by a pancreatic surgeon prior to therapy. This can be confirmed by the surgeon?s documentation in the electronic medical record, by a treatment planning conference note, or by the signature of a pancreatic surgeon
- At least one infusion of FOLFIRINOX, NALIRIFOX, or gemcitabine based chemotherapy must have been attempted.
- No more than 6 months of chemotherapy as defined by standard cycle lengths (every other week infusions for FOLFIRINOX or NALIRIFOX, and 3 infusions per month for gemcitabine-based therapy). Each infusion of FOLFIRINOX or NALIRIFOX will be counted as 0.5 months. Three infusions of gemcitabine based chemotherapy will be counted as 1 month. If chemotherapy is given over a protracted period, then more than 6 months of chemotherapy may be acceptable. For example, if gemcitabine-based therapy is given every other week, then each infusion will still only count as 1/3 of a month toward the 6 month total. If a partial cycle of chemotherapy is given, that partial cycle will be counted proportional to the amount given. For example, if one of three planned infusions of gemcitabine based chemotherapy is given, it will be counted as 1/3 month.
- Enrollment must occur within 90 days of Day 1 of the last infusion given of chemotherapy. Patients who have primary tumor or regional lymph node progression on chemotherapy or prior to enrollment are eligible if no distant metastases are identified on the screening imaging assessment.
- Eastern Cooperative Oncology Group (ECOG) performance status =< 1
- Absolute neutrophil count (ANC) >= 1500/uL
- Platelets >= 100k/uL
- Total Bilirubin =< 2.0 mg/dL
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN)
- Serum creatinine < 1.25 md/dL
- Serum potassium < 5.0 mmol/L
- Negative serum or urine pregnancy test at screening for women of childbearing potential
- Highly effective contraception for both male and female subjects throughout the study and for at least 12 months after last study treatment administration if the risk of conception exists
- Recovery to baseline or =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) v5.0 from toxicities related to any prior treatments, unless AEs are clinically nonsignificant and/or stable on supportive therapy
- Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines
Exclusion Criteria:
- Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen of this trial
- Distant metastases. Regional lymphatic disease is acceptable
- Prior radiation therapy or definitive resection for pancreatic cancer
- Uncontrolled gastric or duodenal ulcer disease within 28 days of registration
- Chronic cough, defined 30% of days over 3 months with active symptoms at enrollment or over 12 months with last active symptoms occurring 6 months prior to enrollment
- Symptomatic hypotension (blood pressure < 90 systolic or < 60 diastolic at screening vital sign assessment) that has the potential to interfere with the patient's safety or ability to complete protocol treatment, at the discretion of the treating investigator
- Patients taking > 50mg losartan QD who, at the discretion of the treating investigator, cannot be reduced to the protocol defined regimen.
- Patients taking an angiotensin II receptor blocker or an angiotensin-converting enzyme inhibitor who, at the discretion of the treating investigator, cannot be safely discontinued prior to Day 1 dosing.
- Patients taking direct renin-angiotensin system inhibitors including aliskiren (Rasilez).
- Prior allergy to an angiotensin II receptor blocker
- Concurrent use of direct renin inhibitor including aliskiren (Rasilez)
Patients with known history of:
- Heart failure. Patients with heart failure, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
- Patients with a prior history of treatment with cardiotoxic agents should be evaluated for heart failure prior to enrollment at the discretion of the treating investigator.
- Solitary kidney, renal artery stenosis, or chronic renal failure
- Human immunodeficiency virus (HIV)-infected patients who are not on effective anti-retroviral therapy or have a detectable viral load within 6 months of trial entry
- Patients with known evidence of chronic hepatitis B virus (HBV) infection and a detectable HBV viral load
- Patients with a history of hepatitis C virus (HCV) infection who have not been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Subject is currently enrolled on another investigational treatment study for pancreas cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (losartan, hypofractionated radiation therapy)
Beginning on day 1, patients receive losartan potassium PO QD.
Beginning day 14, patients also undergo hypofractionated radiation therapy over 15 fractions 5 days a week for up to 3 weeks.
Patients continue to receive losartan potassium PO QD during radiation therapy and for 28 days after completion of radiation therapy.
Patients may begin additional anti-cancer therapy per investigator discretion after the last dose of HRT.
Losartan can be given concurrently with additional therapy and Losartan dosing can continue until 28 days after last dose of HRT, regardless of when additional therapy is started.
|
Ancillary studies
Other Names:
Ancillary studies
Given PO
Other Names:
Undergo hypofractionated radiation therapy
Other Names:
Given PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Grade 3 or higher gastrointestinal toxicity rate
Time Frame: Up to 3 months (84 days) after completion of radiation therapy
|
Will be graded according to Common Terminology Criteria for Adverse Events version (v) 5.0.
The proportion of subjects that experience this endpoint will be tabulated along with an exact 90% binomial confidence interval (Clopper-Pearson).
|
Up to 3 months (84 days) after completion of radiation therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of adverse events
Time Frame: Up to 3 months (84 days) after completion of radiation therapy
|
Will be graded according to Common Terminology Criteria for Adverse Events version (v) 5.0.
|
Up to 3 months (84 days) after completion of radiation therapy
|
Response rate (clinical and/or pathologic partial response [PR] and complete response [CR])
Time Frame: Up to 36 months post-treatment
|
Will be described using Response Evaluation Criteria in Solid Tumors v1.1.
The proportion of subjects with a PR and CR will be reported along with exact binomial confidence intervals (Clopper-Pearson).
|
Up to 36 months post-treatment
|
Progressive free survival (PFS)
Time Frame: From the time of enrollment until disease progression or death (any cause), assessed up to 36 months post-treatment
|
Kaplan-Meier methods will be used to report PFS.
|
From the time of enrollment until disease progression or death (any cause), assessed up to 36 months post-treatment
|
Overall survival (OS)
Time Frame: From the patient?s first dose of study drug to death due to any cause, assessed up to 36 months post-treatment
|
Kaplan-Meier methods will be used to report OS.
|
From the patient?s first dose of study drug to death due to any cause, assessed up to 36 months post-treatment
|
Number patients that require a medical intervention or hospitalization due to hypotension
Time Frame: Up to 36 months post-treatment
|
Will be analyzed descriptively.
|
Up to 36 months post-treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient reported quality of life assessment- review of symptoms and how they interfere in life
Time Frame: At study entry, during the final week of radiation therapy, and at each follow up visit
|
Will be assessed using MD Anderson Symptom Inventory-Gastrointestinal (MDASI-GI).
|
At study entry, during the final week of radiation therapy, and at each follow up visit
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Shane Lloyd, Huntsman Cancer Institute/ University of Utah
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Adenocarcinoma
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Losartan
Other Study ID Numbers
- HCI121104 (Other Identifier: Huntsman Cancer Institute/University of Utah)
- P30CA042014 (U.S. NIH Grant/Contract)
- NCI-2019-05882 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage II Pancreatic Cancer AJCC v8
-
Thomas Jefferson UniversitySuspendedMalignant Solid Neoplasm | Gastric Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Colorectal Adenocarcinoma | Small Intestinal Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC... and other conditionsUnited States
-
Thomas Jefferson UniversityRecruitingStage II Pancreatic Cancer AJCC v8 | Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8 | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic Ductal AdenocarcinomaUnited States
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)CompletedStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer... and other conditionsUnited States
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH); National...Not yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Squamous Cell... and other conditionsUnited States
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; Servier Pharmaceuticals...RecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnPancreatic Ductal Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Homologous Recombination Deficiency | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | ATM Gene Mutation | Deleterious BRCA1 Gene... and other conditions
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingStage III Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Malignant Female Reproductive System Neoplasm | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical Cancer AJCC v8 | Stage IB Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IV Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB... and other conditionsUnited States
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Breast Carcinoma | Head and Neck Carcinoma | Lung Carcinoma | Esophageal Carcinoma | Malignant Digestive System Neoplasm | Malignant Central Nervous System Neoplasm | Genitourinary System CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBreast Carcinoma | Cancer SurvivorUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedFallopian Tube Cancer | Recurrent Endometrial Carcinoma | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Recurrent Uterine Sarcoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Recurrent Ovarian Epithelial Cancer | Stage IV Endometrial Carcinoma | Ovarian... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States